Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1198

HUTCHISON CHINA MEDITECH LIMITED

(HCM)
  Report
SummaryQuotesNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Most relevant news about HUTCHISON CHINA MEDITECH L
03/31Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Mali..
GL
03/26Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
03/10International companies to host live webcasts at Deutsche Bank's Depositary R..
AQ
03/03HUTCHISON CHINA MEDITECH : Chi-Med Reports 2019 Full Year Results and Provides U..
AQ
03/03HUTCHISON CHINA MEDITECH : Form-20F Publication
PU
03/03HUTCHISON CHINA MEDITECH : Final Results and Clinical Update
PU
02/25Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adju..
GL
02/10HUTCHISON CHINA MEDITECH : Chi-Med Highlights Updated Phase II Savolitinib / Imf..
AQ
02/10HUTCHISON CHINA MEDITECH : Phase II Savolitinib / Imfinzi® Combination Data
PU
02/06Chi-Med Announces the Exercise of Underwriters' Over-allotment Option for Pub..
GL
01/31HUTCHISON CHINA MEDITECH : Chi-Med to Announce 2019 Final Results
AQ
01/31Chi-Med to Announce 2019 Final Results
GL
01/23Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs
GL
01/21HUTCHISON CHINA MEDITECH : Chi-Med Announces Proposed Public Offering of ADSs
AQ
01/20HUTCHISON CHINA MEDITECH : Chi-Med Announces that Surufatinib Phase III SANET-p ..
AQ
01/13HUTCHISON CHINA MEDITECH : Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
PU
01/13Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi i..
GL
01/06HUTCHISON CHINA MEDITECH : Chi-Med to Present at the 38th Annual JP Morgan Healt..
AQ
01/06HUTCHISON CHINA MEDITECH : Chi-Med to Present at JP Morgan Conference
PU
2019HUTCHISON CHINA MEDITECH : Surufatinib Granted Priority Review in China
PU
2019Chi-Med's New Drug Application for Surufatinib in Non-Pancreatic Neuroendocri..
GL
2019Chi-Med's Elunate® (Fruquintinib Capsules) Included in the National Reimburse..
GL
2019HUTCHISON CHINA MEDITECH : Elunate® Included in China NRDL
PU
2019HUTCHISON CHINA MEDITECH : Chi-Med Highlights Presentations at 2019 ESMO Asia
PU
2019Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancrea..
GL
2019HUTCHISON CHINA MEDITECH : Surufatinib granted FDA orphan drug designation
PU
2019HUTCHISON CHINA MEDITECH : Chi-Med Highlights Oral Presentations at 2019 ESMO As..
AQ
2019Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
2019Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic N..
GL
2019International companies to host live webcasts at Deutsche Bank's Depositary R..
AQ
2019Chi-Med highlights publication of Phase II data showing promising efficacy fo..
GL
2019HUTCHISON CHINA MEDITECH : Chi-Med highlights publication of Phase II data showi..
AQ
2019Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients w..
GL
2019CK HUTCHISON : Hutchison China MediTech Shares in London Fall as Investor Plans ..
DJ
2019CK Hutchison prices offering of Chi-Med share capital enabling deconsolidatio..
GL
2019CK HUTCHISON : Hutchison China MediTech Shares in London Fall as Investor Plans ..
DJ
2019HUTCHISON CHINA MEDITECH : CK Hutchison offers 1.3% of Chi-Med's share capital a..
AQ
2019Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Saf..
GL
2019Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep..
GL
2019Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
GL
2019Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Prima..
GL
Upcoming event on HUTCHISON CHINA MEDITECH L